Marché mondial du traitement du lymphome non hodgkinien et du lymphome chronique – Tendances et prévisions du secteur jusqu'en 2029

Analyse du marché et perspectives du marché du traitement du lymphome non hodgkinien et du lymphome chronique

Data Bridge Market Research analyse que le traitement du lymphome non hodgkinien et du lymphome chronique affichera un TCAC d'environ 7,75 % pour la période de prévision 2022-2029. La demande croissante de modes de thérapies ciblés, l'augmentation des activités de recherche et développement pour le développement de nouveaux médicaments et thérapies, l'augmentation des cas de cancer et de maladies chroniques au sein de la population et l'augmentation des dépenses pour le développement des infrastructures de santé sont les principaux facteurs attribuables à la croissance du marché du traitement du lymphome non hodgkinien et du lymphome chronique.

Le lymphome est un terme plus large pour désigner le cancer. Il débute dans le système lymphatique. Le lymphome non hodgkinien est un cancer qui se développe dans les globules blancs. Il attaque et détruit le système immunitaire du patient, ce qui entraîne l'apparition de plusieurs maladies.  

L'augmentation des désignations spéciales des autorités réglementaires est un facteur majeur favorisant la croissance du marché. L'augmentation des dépenses consacrées au développement des infrastructures de santé, la sensibilisation croissante du public au lymphome non hodgkinien et aux médicaments déjà en cours de développement, l'augmentation des initiatives du gouvernement pour promouvoir la sensibilisation au cancer et à d'autres maladies potentiellement mortelles dans les régions défavorisées et la montée en flèche du taux de collaboration stratégique entre les acteurs du marché sont d'autres facteurs favorisant également la croissance du marché. La prévalence croissante de la médecine personnalisée parmi les patients est un autre facteur déterminant qui créera des opportunités de croissance lucratives du marché.

However, dearth of skilled medical professionals and unfavourable reimbursement scenario in the developing and under developed economies will pose a major challenge to the market growth. Also, high costs associated with research and development proficiencies, rising cost treatment and drugs still yet to be approved by the specific authorities and poor healthcare facilities in the underdeveloped economies will further derail the market growth rate. Side effects associated with chemotherapy will also hamper the market growth rate.

This non-hodgkin’s lymphoma and chronic lymphoma treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on non-hodgkin’s lymphoma and chronic lymphoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market Scope and Market Size

The non-hodgkin’s lymphoma and chronic lymphoma treatment market is segmented on the basis of treatment type, cell type, route of administration and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on treatment type, the non-hodgkin’s lymphoma and chronic lymphoma treatment market is segmented into in chemotherapy, immunotherapy, targeted therapy, radiation and stem cell transplant.
• Non-hodgkin’s lymphoma and chronic lymphoma treatment market has also been segmented based on the cell type into B-cell and T-cell.
• Based on the route of administration, the non-hodgkin’s lymphoma and chronic lymphoma treatment market is segmented into intravenous, subcutaneous, intrathecal route, intramuscular and oral.
• Based on end user, the non-hodgkin’s lymphoma and chronic lymphoma treatment market is segmented into hospitals, ambulatory surgical centers, cancer institutes and research, academic institutes and others.

Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market Country Level Analysis

The non-hodgkin’s lymphoma and chronic lymphoma treatment market is analysed and market size insights and trends are provided by country, treatment type, cell type, route of administration and end user as referenced above.

The countries covered in the non-hodgkin’s lymphoma and chronic lymphoma treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the non-hodgkin’s lymphoma and chronic lymphoma treatment market owing to the earliest adoption of innovative technologies, growing research and development capacities, rise in awareness about the treatment and management of chronic diseases, and well-structured regulatory framework. Asia-Pacific is projected to undergo substantial gains during the forecast period and score the highest CAGR. This is because of the rising expenditure to develop healthcare infrastructure, and increase in the research and development activities.

The country section of the non-hodgkin’s lymphoma and chronic lymphoma treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The non-hodgkin’s lymphoma and chronic lymphoma treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to non-hodgkin’s lymphoma and chronic lymphoma treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the non-hodgkin’s lymphoma and chronic lymphoma treatment market in the growth period.

Competitive Landscape and Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market Share Analysis

Le paysage concurrentiel du marché du traitement du lymphome non hodgkinien et du lymphome chronique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du traitement du lymphome non hodgkinien et du lymphome chronique.

Certains des principaux acteurs opérant sur le marché du traitement du lymphome non hodgkinien et du lymphome chronique sont F. Hoffman-La Roche Ltd., Johnson & Johnson, Services, Inc., Bayer AG, Eli Lilly and Company, Amgen Inc., Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Kite Pharma. Inc., GlaxoSmithKline plc., CELGENE CORPORATION, Merck & Co., Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, ALLERGAN, Accredo Health Group Inc., Baxter, Teva Pharmaceutical Industries Ltd., Cook et Lupin, entre autres.

SKU-26316